Intermountain Precision Genomics Call for Research Proposals

Translational research plays an important role in helping people live the healthiest lives possible. We strive to support researchers and investigators by combining expertise in next generation sequencing with emphasis on projects in precision medicine. Currently we offer capabilities in whole genome, exome, cfDNA and RNA sequencing as well as single cell and mass cytometry services. Our access to samples through the Intermountain Biorepository and the Intermountain Healthcare Network for prospective and retrospective studies will leverage your best ideas. We aim to help you link genomics to innovation.


Apply for Spring 2019 Collaborative Research Proposals

Intermountain Precision Genomics is now calling for brief research proposals to be submitted by groups interested in using NGS ONE Genomic Services high-throughput sequencing either in conjunction with the Intermountain Biorepository or as standalone sequencing services for precision medicine applications.

Intermountain Precision Genomics will fund up to $200,000 total investment for proposals that are innovative, creative, and advance our mission of helping people live the healthiest lives possible. Funds are designated to cover upcoming costs of procuring, preparing, and sequencing samples at Intermountain, and exclude indirect costs, investigator salaries, and expenses already incurred in the acquisition and preparation of project samples. All awarded funding must be expended at Intermountain facilities and cannot be disbursed to third parties.

Applications will be evaluated by a panel of scientists from different biomedical disciplines and should be written for this audience. Projects will be evaluated on the likelihood of providing scientific impact and influence on the research field involved using the National Institutes of Health (NIH) review criteria of assessing significance, innovation, and approach. It is expected that project awards will result in one or more peer-reviewed publications and provide pilot data for larger collaborative endeavors or extramural grant applications.

The following applicant organizations are eligible to apply:

  • Institutions of higher education
  • Nonprofits other than institutions of higher education
  • Small businesses
  • For-profit organizations including commercial, biotechnology and pharmaceutical industries (other than small businesses)

Non-United States (U.S.) institutions or foreign components of U.S. organizations are NOT eligible to apply.

Email to request an application. After receipt, use the application template to submit proposals and return via email with attention to the Research Review Committee.

Submitted proposals will be held confidential. A non-disclosure agreement can be arranged if intellectual property intends to be included in the application.

Spring submission deadline: April 30, 2019.

Selected projects will be announced by May 31, 2019.


Learn More About NGS ONE™ Genomic Services

NGS ONE enables researchers to accelerate their precision medicine projects by providing them with high-quality next-generation sequencing data and rapid turnaround times at a competitive price.

This innovative and intuitive service offers a simple, straightforward, and convenient way to order sequencing for whole genomes, exomes, and RNA-Seq. NGS ONE's affiliation with Intermountain Healthcare and daily experience working with patient samples makes it unique in the industry, and an ideal resource for all your future next-generation sequencing projects.

Learn more >


Fall 2019 Application Cycle

Intermountain Precision Genomics' next biannual call for proposals will be fall 2019. Future research proposals may qualify for the second application cycle of the year. Further details to come.

Fall 2019 submissions will open in late summer 2019, after spring project announcements.


2018 Awardees

Stanford University

Prediction of undiagnosed cases of familial hypercholesterolemia. Carlos Bustamante, PhD, Professor of biomedical data science, genetics, and biology at Stanford University

Huntsman Cancer Institute

Novel germline breast cancer susceptibility variants - Nicola Camp, PhD, Hunstman Cancer Institute investigator, professor of medicine at the University of Utah School of Medicine

Genetic epidemiology of ovarian cancers in high-risk pedigrees - Jennifer Doherty, PhD, MS, Huntsman Cancer Institute investigator, associate professor of population health sciences at the University of Utah School of Medicine

Vivid Genomics

Genetic risks of Alzheimer's and other neurodegenerative diseases - Damian Wheeler, PhD, Vivid Genomics Principal Investigator